Culture results | Intracameral moxifloxacin | Susceptibility to antibiotics | ||||
No | Yes | Moxifloxacin N (%) | Ceftazidime N (%) | Vancomycin N (%) | Gentamycin N (%) | |
CONS | 11 | 0 | 8 (72.8) | 6 (54.5) | 10 (90.1) | 3 (27) |
Staphylococcus aureus | 9 | 1 | 8 (80) | 5 (50) | 9 (90) | 5 (50) |
Streptococcus species | 3 | 0 | 3 (100) | 2 (66.6) | 3 (100) | 2 (66.6) |
Haemophilus species | 2 | 0 | 2 (100) | 2 (100) | *– | 1 (50) |
Klebsiella species | 1 | 0 | 1 (100) | 1 (100) | *– | 1 (100) |
Proteus species | 1 | 0 | 1 (100) | 1 (100) | *– | 1 (100) |
Clostridium species | 1 | 0 | 1 (100) | 0 | 1 (100) | *– |
No growth | 88 | 7 | – | – | – | – |
Total | 116 | 8 | – | – | – | – |
Susceptible break points for major isolated organisms (Clinical Laboratory Standards Institute guidelines): Moxifloxacin (5 ug): CONS 28 mm, Staphylococcus aureus 24 mm, Streptococcus sp. 18 mm; Ceftazidime (30 ug): CONS 25 mm, S. aureus 22 mm; Streptococcus sp. 24 mm; Vancomycin: CONS 4 ug/mL (MIC), S. aureus 2 ug/mL (MIC); Streptococcus sp. 17 mm (30 ug); Gentamycin (10 ug): CONS 15 mm, S. aureus: 15 mm, Streptococcus sp. 15 mm.
*In-vitro sensitivity tests for these antibiotics were not performed.
CONS, coagulase-negative staphylococci; MIC, minimum inhibitory concentration.